Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
Sebi extends deadline to Jan 2026 to disclose allocation methodology by angel funds
15/10/2025
Swiggy, Eternal to see margins improve in Q2FY26 : Analysts
15/10/2025
20+ MFs added these 12 stocks in September '25 ; one turned multibagger. Do you own any ?
15/10/2025
Gold ETFs see more than 6X YoY rise in September inflows amid geopolitical tensions and rising prices : ICRA Analytics
15/10/2025
Missed the LG Electronics India IPO ? What should you do as stock trades 48% above issue price ?
15/10/2025
What to watch for at China's Communist Party's plenum
15/10/2025
